NasdaqGS - Delayed Quote USD

Dyne Therapeutics, Inc. (DYN)

24.98 -0.46 (-1.81%)
At close: April 24 at 4:00 PM EDT
24.50 -0.48 (-1.92%)
After hours: April 24 at 6:27 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Susanna Gatti High M.B.A. Chief Operating Officer 754.1k -- 1968
Dr. Jonathan McNeill M.D. Chief Business Officer 662.34k -- 1985
Mr. John G. Cox M.B.A. CEO, President & Director -- -- 1963
Dr. Romesh Subramanian Ph.D. Co-Founder & Advisor 565.17k -- 1965
Mr. Richard William Scalzo M.B.A. Senior VP and Head of Finance & Administration -- -- 1986
Mr. John Najim M.B.A. Chief Technical Officer -- -- --
Dr. Oxana Beskrovnaya Ph.D. Chief Scientific Officer 631.08k -- 1961
Ms. Amy Reilly Senior VP and Head of Corporate Communications & Investor Relations -- -- 1974
Mr. Daniel Wilson Senior VP & Head of Legal -- -- 1972
Ms. Kate Mitchell VP & Head of Human Resources -- -- --

Dyne Therapeutics, Inc.

1560 Trapelo Road
Waltham, MA 02451
United States
781 786 8230 https://www.dyne-tx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
141

Description

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Dyne Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Dyne Therapeutics, Inc. Earnings Call

Related Tickers

RNA Avidity Biosciences, Inc.
25.09
-0.20%
 
MLTX MoonLake Immunotherapeutics
42.43
-1.90%
 
MRUS Merus N.V.
41.97
+2.82%
 
APGE Apogee Therapeutics, Inc.
46.54
-6.49%
 
RVMD Revolution Medicines, Inc.
35.59
-1.85%
 
KROS Keros Therapeutics, Inc.
56.24
+1.90%
 
SWTX SpringWorks Therapeutics, Inc.
43.38
-1.41%
 
EWTX Edgewise Therapeutics, Inc.
16.11
+2.94%
 
CGON CG Oncology, Inc.
36.05
-0.72%
 
FDMT 4D Molecular Therapeutics, Inc.
24.25
-2.26%